alexa Abstract | A Rationale for Maintaining Current Tigecycline Breakpoints as Established by the USA Food and Drug Administration

Archives of Clinical Microbiology
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access

Abstract

Background: Tigecycline has demonstrated good rates of microbiological eradication and clinical cure among indicated infections [Complicated intra- Abdominal infections (cIAIs), complicated Skin and Skin Structure Infections (cSSSI), Community-Acquired Bacterial Pneumonia (CAP), in the USA]. This investigation evaluates the FDA approved breakpoints for tigecycline using microbiological and clinical data derived from cSSSI, cIAI and CAP clinical trials.
Methods and findings: Clinical and microbiological success rates from phase III and phase IIIb/IV clinical trials were analyzed by MIC. Additionally, a surveillance program was utilized to assess changes in the antimicrobial potency of tigecycline between 2004 and 2012. Microbiological eradiation and clinical cure rates for patients with infections caused by Enterobacteriaceae at a tigecycline MIC of ≤2 mg/L or S. aureus with a tigecycline MIC of ≤0.5 mg/L were ≥81%. Against tigecycline non-susceptible pathogens microbiological and clinical successes were reported for 13/22 (59.1%) and 12/22 (54.5%), respectively. Using the Fisher’s exact test a comparison of microbiological success rates for patients (ME population) with Enterobacteriaceae with tigecycline MICs of ≤2 mg/L (n=922) and ≥4 mg/L (n=16) yielded a statistically significant two-tailed P value of 0.046. In the case of S. aureus, a comparison of MICs of ≤0.5 mg/L (n=287) and ≥1 mg/L (n=1) gave no statistically significant difference (P=1.000). Using the Cochran Armitage trend test statistically significant increases in tigecycline in vitro susceptibility were observed for Enterobacter spp. (p<0.01) and Enterobacteriaceae (p<0.01) and a statistically significant decrease in susceptibility among Enterococcus faecium (p<0.0001).
Conclusions: The current clinical FDA breakpoints for tigecycline are appropriate. Only E. faecium has shown a statistically significant decrease in susceptibility to tigecycline since tigecycline was first introduced into clinical practice in the USA in 2005.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): David P Nicolau Alvaro Quintana Joan M Korth Bradley Michele Wible Michael J Dowzicky

Keywords

Tigecycline, Susceptibility breakpoints, Antimicrobial resistance, Tigecycline, Susceptibility breakpoints, Antimicrobial resistance

 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords